Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | PPARG | P37231 | 1/20 | 0.68 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.68 |
| ▸ | FABP3 | P05413 | 1/20 | 0.60 |
| ▸ | FABP4 | P15090 | 1/20 | 0.60 |
| ▸ | DHODH | Q02127 | 8/20 | 0.56 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.51 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27489637 | 0.83 | PTGS2 (0.53) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL27595572 | 0.81 | PTGS2 (0.64) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| Lumiracoxib SCHEMBL29475008 | 0.81 | PTGS2 (1.00) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| Lumiracoxib SCHEMBL29377334 | 0.81 | PTGS2 (1.00) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| Lumiracoxib SCHEMBL4479 | 0.81 | PTGS2 (1.00) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL26193724 | 0.80 | PTGS2 (0.62) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| Lumiracoxib SCHEMBL27680523 | 0.80 | PTGS2 (0.98) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL6024132 | 0.79 | PTGS2 (0.61) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL5533958 | 0.79 | PTGS2 (0.82) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL3120262 | 0.79 | PTGS2 (0.82) | PTGS2PTGS1ABCB11PPARGNR1I3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322874-A1 | Pharmaceutical Uses | BRAZZELL ROMULUS KIMBRO (US) | 2012-12-20 | — | — | US | disclosed |
| US-20090247638-A1 | PHARMACEUTICAL USE OF COX-2-INHIBITORS IN ANGIOGENESIS-MEDIATED OCULAR DISORDERS | BRAZZELL ROMULUS KIMBRO | 2009-10-01 | — | — | US | disclosed |
| CN-100490797-C | Pharmaceutical composition | NOVARTIS AG (CH) | 2009-05-27 | — | — | CN | disclosed |
| EP-2014284-A1 | Pharmaceutical compositions and uses | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008156645-A2 | PHARMACEUTICAL COMPOSITIONS AND USES | NOVARTIS AG (CH) | 2008-12-24 | — | — | WO | disclosed |
| US-20080146662-A1 | Methods and compositions for treatment of cancer pain | FUJIMOTO ROGER AKI | 2008-06-19 | — | — | US | disclosed |
| US-7345088-B2 | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol | PENN STATE RESEARCH FOUNDATION (US) | 2008-03-18 | — | — | US | disclosed |
| CN-100372539-C | Pharmaceutical composition comprising a combination of a bisphosphonate, a COX-2 inhibitor and paclitaxel for the treatment of malignancies | NOVARTIS AG (CH) | 2008-03-05 | — | — | CN | disclosed |
| US-20080027032-A1 | COMBINATIONS COMPRISING COX-2 INHIBITORS AND ASPIRIN | GIMONA ALBERTO | 2008-01-31 | — | — | US | disclosed |
| EP-1443942-B1 | PHARMACEUTICAL COMPOSITION FOR USE FOR THE TREATMENT OF MALIGNANCIES COMPRISING IN COMBINATION A BISPHOSPHONATE, A COX-2 INHIBITOR AND A TAXOL | NOVARTIS AG (CH) | 2008-01-02 | — | — | EP | disclosed |
| WO-2002020090-A9 | PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003072097-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BISPHOSPHONATE AND A COX-2 INHIBITOR FOR THE TREATMENT OF BONE DISEASES | NOVARTIS AG (CH) | 2003-09-04 | — | — | WO | disclosed |
| EP-1331972-A2 | PHARMACEUTICAL COMPOSITIONS | Novartis AG (CH) | 2003-08-06 | — | — | EP | disclosed |
| WO-2003061645-A1 | PHARMACEUTICAL USE OF COX-2 INHIBITORS IN ANGIOGENESIS-MEDIATED OCULAR DISORDERS | NOVARTIS AG (CH) | 2003-07-31 | — | — | WO | disclosed |
| US-20030114527-A1 | Pharmaceutical composition | NOVARTIS AG (CH) | 2003-06-19 | — | — | US | disclosed |
| WO-2003035081-A1 | PHARMACEUTICAL COMPOSITION FOR USE FOR THE TREATMENT OF MALIGNANCIES COMPRISING IN COMBINATION A BISPHOSPHONATES, A COX-2 INHIBITOR AND A TAXOL | NOVARTIS AG (CH) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003033001-A1 | COMBINATIONS COMPRISING COX-2 INHIBITORS AND ASPIRIN | NOVARTIS AG (CH) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003020261-A1 | PHARMACEUTICAL COMPOSITION COMPRISING LUMIRACOXIB | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
| US-20020061932-A1 | Pharmaceutical composition | GIMONA ALBERTO (CH) | 2002-05-23 | — | — | US | disclosed |
| WO-2002020090-A2 | PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247638-A1 | PHARMACEUTICAL USE OF COX-2-INHIBITORS IN ANGIOGENESIS-MEDIATED OCULAR DISORDERS | PTGS2, PTGS1, PTGES2 | PTGS2 1/4885PTGS1 2/4885ABCB11 2995/4885 |
| US-20080027032-A1 | COMBINATIONS COMPRISING COX-2 INHIBITORS AND ASPIRIN | PTGS2, PTGER2, PTGES2 | PTGS2 1/4885PTGS1 4/4885ABCB11 3306/4885 |
| US-20080146662-A1 | Methods and compositions for treatment of cancer pain | PTGER2, PTGS2, PTGES2 | PTGS2 2/4885PTGS1 5/4885ABCB11 1383/4885 |
| US-20120322874-A1 | Pharmaceutical Uses | PTGS2, PTGS1, PTGES2 | PTGS2 1/4885PTGS1 2/4885ABCB11 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.